Published in Clinical Oncology Week, August 29th, 2005
NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH), which the company believes shows good promise as a potential first-line treatment for BPH. In two completed trials in the U.S. to date, the drug has shown highly significant efficacy without significant side effects. The company's large phase 2 trial is expected to be completed later this year.
In the phase 1-2 trials to date, the subjects treated with NX-1207 showed a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.